Arkolith/Insider Trading/DFFN/Form 4/A

Cobuzzi Robert Joseph Jr.

President & CEO, DirectorDiffusion Pharmaceuticals Inc. (DFFN) · full profile →Form 4/A · filed Feb 2, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 1, 2021Disposed to issuer(D)6K——24K
Nov 1, 2021Option exercise(M)16K——30K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 1, 2021Option exercise(M)16K—$082K

Transaction Codes

D
Disposition to the issuer
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001437749-22-002263) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML